| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
Erianin targets multiple molecular pathways. It is a small molecule inhibitor of CRAF and MEK1/2 kinases, and it inhibits the constitutive activation of the MAPK signaling pathway. Unlike some other inhibitors, it does not inhibit BRAF kinase activity. Erianin also potently inhibits pyruvate carboxylase (PC) with an IC50 of 5 nM. Furthermore, it inhibits indoleamine-2,3-dioxygenase (IDO)-induced tumor angiogenesis. This multi-targeted approach contributes to its diverse biological activities, including its antitumor, anti-inflammatory, and analgesic effects.
|
|---|---|
| ln Vitro |
Erianin is a common analgesic and antipyretic. Erianin possesses antiviral, antibacterial, and anti-benign prostatic hyperplasia properties, among other things. Its structure is a bibenzyl derivative. 2LL-IDO cells are significantly harmed by eryanin. The human normal liver cell line L02 exhibits nearly minimal cytotoxicity when exposed to eryanin, and cell viability is preserved at 85% [1]. In a dose- and time-dependent way, eryanin suppresses the development of HeLa cells and triggers apoptosis, resulting in cell cycle arrest in the G2/M phase. Bax and caspase-3 expression was likewise upregulated upon eryanin administration, although Bcl-2 and phospho-ERK1/2 levels were downregulated [2].
In vitro, Erianin has demonstrated significant antitumor activity. It regulates a variety of cancer-associated pathways, including apoptosis, cell-cycle arrest, invasion, migration, and autophagy. It inhibits the constitutive activation of the MAPK signaling pathway by suppressing CRAF and MEK1/2 kinase activity. Erianin also inhibits IDO-induced tumor angiogenesis. Its antibacterial, antiviral, and anti-benign prostatic hyperplasia properties have also been noted. The compound's in vitro activities are typically assessed using various cancer cell lines and biochemical assays. |
| ln Vivo |
In vivo, Erianin has been studied for its potential anti-inflammatory, antioxidant, and anticancer activities. Its ability to inhibit tumor growth and induce apoptosis makes it a subject of interest in cancer research. In traditional medicine, it has been used as an analgesic. Studies have shown that Erianin can cause extensive tumor necrosis and growth delay. However, detailed in vivo efficacy data are not extensively documented in the public literature. Further studies, including animal models of cancer and inflammation, are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
For in vitro enzyme assays, the activity of Erianin is assessed by measuring its inhibition of CRAF, MEK1/2, and pyruvate carboxylase. Kinase assays are performed using purified enzymes and appropriate substrates in the presence of ATP. The inhibition of MAPK signaling is confirmed by Western blotting for phosphorylated ERK. IDO activity can be measured by the production of kynurenine.
|
| Cell Assay |
For in vitro cell-based assays, the antitumor activity of Erianin is evaluated using various cancer cell lines. Cells are treated with the compound, and cell viability is measured using MTT or CCK-8 assays. Apoptosis is assessed by Annexin V staining, caspase activity assays, or DNA fragmentation analysis. Cell cycle distribution is analyzed by flow cytometry. Cell invasion and migration are assessed using transwell or wound-healing assays. The compound's effects on autophagy are studied by measuring LC3-II and p62 levels.
|
| Animal Protocol |
For in vivo animal studies, Erianin is typically administered orally or intraperitoneally in rodent models of cancer or inflammation. To evaluate its antitumor efficacy, xenograft models of various cancers can be used. Tumor-bearing mice are treated with the compound, and tumor growth and weight are monitored. To evaluate its anti-inflammatory effects, models of acute or chronic inflammation can be used. The compound's effects on pain can be assessed using pain models such as the hot plate or formalin tests.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Erianin: The compound has a molecular formula of C18H22O5 and a molecular weight of 318.36. It is typically stored as a powder at -20°C. As a small, lipophilic molecule, it is expected to have reasonable oral bioavailability. Detailed pharmacokinetic parameters, such as half-life and tissue distribution, are not extensively available in the public literature.
|
| Toxicity/Toxicokinetics |
Specific toxicity data for Erianin are limited. The compound is used as a research tool and is not intended for human therapeutic use. As a potent inhibitor of multiple targets, it may have off-target effects. Comprehensive toxicological studies have not been published. Standard laboratory safety precautions should be observed.
|
| References |
|
| Additional Infomation |
Reports indicate that Dendrobium nobile and Dendrobium grandiflorum contain erythrone, and relevant data is available for reference.
Erianin is a research compound with no clinical trial or regulatory approval status. It is a natural product extracted from Dendrobium chrysotoxum and has a wide range of biological activities, including antitumor, anti-inflammatory, and analgesic effects. It is commercially available from chemical suppliers for research purposes only. The compound is a subject of interest in cancer research and natural product drug discovery. |
| Molecular Formula |
C₁₈H₂₂O₅
|
|---|---|
| Molecular Weight |
318.36
|
| Exact Mass |
318.146
|
| CAS # |
95041-90-0
|
| PubChem CID |
356759
|
| Appearance |
White to off-white solid powder
|
| Density |
1.1±0.1 g/cm3
|
| Boiling Point |
439.1±40.0 °C at 760 mmHg
|
| Flash Point |
219.4±27.3 °C
|
| Vapour Pressure |
0.0±1.1 mmHg at 25°C
|
| Index of Refraction |
1.554
|
| LogP |
3.11
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
23
|
| Complexity |
323
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
UXDFUVFNIAJEGM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C18H22O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h7-11,19H,5-6H2,1-4H3
|
| Chemical Name |
2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~314.11 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.53 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.53 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.53 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1411 mL | 15.7055 mL | 31.4110 mL | |
| 5 mM | 0.6282 mL | 3.1411 mL | 6.2822 mL | |
| 10 mM | 0.3141 mL | 1.5705 mL | 3.1411 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
